SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,182,919 | -56.5% | 57,479 | -0.7% | 0.00% | -100.0% |
| Q2 2023 | $2,721,564 | +29.0% | 57,881 | +15.1% | 0.00% | 0.0% |
| Q1 2023 | $2,109,749 | +22.7% | 50,280 | +11.5% | 0.00% | 0.0% |
| Q4 2022 | $1,720,039 | -2.9% | 45,098 | -0.3% | 0.00% | 0.0% |
| Q3 2022 | $1,772,000 | +11.8% | 45,251 | -7.8% | 0.00% | 0.0% |
| Q2 2022 | $1,585,000 | -48.1% | 49,064 | -46.8% | 0.00% | 0.0% |
| Q1 2022 | $3,056,000 | -16.3% | 92,307 | +7.5% | 0.00% | 0.0% |
| Q4 2021 | $3,653,000 | -12.0% | 85,871 | -8.4% | 0.00% | 0.0% |
| Q3 2021 | $4,152,000 | -12.6% | 93,703 | +12.0% | 0.00% | -50.0% |
| Q2 2021 | $4,751,000 | +98.1% | 83,645 | +161.1% | 0.00% | +100.0% |
| Q1 2021 | $2,398,000 | -12.3% | 32,035 | +1.3% | 0.00% | 0.0% |
| Q4 2020 | $2,735,000 | +5.7% | 31,612 | -25.3% | 0.00% | 0.0% |
| Q3 2020 | $2,588,000 | +48.9% | 42,342 | +1.3% | 0.00% | 0.0% |
| Q2 2020 | $1,738,000 | +54.1% | 41,785 | +6.3% | 0.00% | 0.0% |
| Q1 2020 | $1,128,000 | -60.5% | 39,298 | -0.7% | 0.00% | 0.0% |
| Q4 2019 | $2,858,000 | -41.2% | 39,581 | +14.3% | 0.00% | -66.7% |
| Q3 2019 | $4,859,000 | -11.7% | 34,638 | +15.3% | 0.00% | 0.0% |
| Q2 2019 | $5,501,000 | +36.0% | 30,044 | +18.1% | 0.00% | +50.0% |
| Q1 2019 | $4,046,000 | +83.3% | 25,443 | +10.4% | 0.00% | 0.0% |
| Q4 2018 | $2,207,000 | -26.1% | 23,039 | +9.0% | 0.00% | 0.0% |
| Q3 2018 | $2,985,000 | -9.7% | 21,137 | +0.1% | 0.00% | -33.3% |
| Q2 2018 | $3,305,000 | +16.7% | 21,116 | +20.1% | 0.00% | +50.0% |
| Q1 2018 | $2,831,000 | +1.3% | 17,581 | +3.7% | 0.00% | 0.0% |
| Q4 2017 | $2,796,000 | +202.6% | 16,952 | +14.4% | 0.00% | +100.0% |
| Q3 2017 | $924,000 | -4.6% | 14,820 | +21.2% | 0.00% | 0.0% |
| Q2 2017 | $969,000 | +28.3% | 12,232 | +13.8% | 0.00% | 0.0% |
| Q1 2017 | $755,000 | +51.9% | 10,748 | +9.5% | 0.00% | – |
| Q4 2016 | $497,000 | +89.7% | 9,814 | +71.7% | 0.00% | – |
| Q3 2016 | $262,000 | +66.9% | 5,715 | +5.6% | 0.00% | – |
| Q2 2016 | $157,000 | +17.2% | 5,414 | +30.6% | 0.00% | – |
| Q1 2016 | $134,000 | -34.6% | 4,146 | +17.2% | 0.00% | – |
| Q4 2015 | $205,000 | +113.5% | 3,539 | +52.5% | 0.00% | – |
| Q3 2015 | $96,000 | -41.1% | 2,321 | 0.0% | 0.00% | – |
| Q2 2015 | $163,000 | – | 2,321 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |